Factors Associated With Sacubitril/Valsartan Continuation and the Methods of Combining Heart Failure Medications in Patients With Heart Failure.
與心衰竭患者持續使用 Sacubitril/Valsartan 相關的因素及心衰竭藥物組合的方法。
Ann Pharmacother 2024-09-04
Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure.
SGLT2 抑制劑在心臟衰竭住院後真實世界人群中停用的預測因子和結果。
Biomedicines 2023-03-31
Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction.
心臟衰竭患者合併左心室射血分數降低症狀,接受 sacubitril/valsartan 與 dapagliflozin 聯合治療。
Front Cardiovasc Med 2023-11-02
Efficacy of sacubitril-valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta-analysis.
心臟衰竭伴隨降低射出分數的 sacubitril-valsartan 和 SGLT2 抑制劑的療效:系統性回顧與荟萃分析。
Clin Cardiol 2023-10-23
The Worsening Renal Perfusion Index Predicts the Prognoses of Heart Failure Patients Treated with Sacubitril/Valsartan.
腎臟灌注指數惡化可預測接受 Sacubitril/Valsartan 治療的心衰患者的預後。
Cardiorenal Med 2024-03-19
Treatment with sacubitril/valsartan effectively manages hypertension and ameliorates left ventricular hypertrophy in hemodialysis patients.
在血液透析患者中,使用sacubitril/valsartan治療有效地控制高血壓並改善左心室肥厚。
Blood Purif 2024-06-02
The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis.
Sacubitril/valsartan在心衰合併異常腎功能患者中的作用:一項荟萃分析和系統分析。
Ren Fail 2024-06-13
Empagliflozin combined with sacubitril/valsartan in hypertensive patients with heart failure: a retrospective study of efficacy and effect on blood pressure variability and cardiac function.
Empagliflozin 與 sacubitril/valsartan 併用於高血壓心衰竭患者的療效及對血壓變異性和心臟功能影響的回顧性研究。
Am J Transl Res 2024-08-08
Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials.
Sacubitril/Valsartan 對心衰竭全因住院的影響:PARADIGM-HF 和 PARAGON-HF 隨機臨床試驗的事後分析。
JAMA Cardiol 2024-08-30